Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
12 studies found for:    pegph20
Show Display Options
Rank Status Study
1 Not yet recruiting PEGPH20 Plus Gemcitabine With Radiotherapy in Patients With Localized, Unresectable Pancreatic Cancer
Condition: Pancreatic Adenocarcinoma Non-resectable
Interventions: Drug: PEGylated Recombinant Human Hyaluronidase (PEGPH20);   Drug: Gemcitabine;   Radiation: Radiation
2 Active, not recruiting PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Subjects With Stage IV Untreated Pancreatic Cancer
Condition: Metastatic Pancreatic Cancer
Interventions: Drug: PEGPH20+nab-paclitaxel+gemcitabine;   Drug: nab-paclitaxel + gemcitabine
3 Recruiting Study of Eribulin Mesylate in Combination With PEGylated Recombinant Human Hyaluronidase (PEGPH20) Versus Eribulin Mesylate Alone in Subjects With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative, High-Hyaluronan (HA) Metastatic Breast Cancer (MBC)
Condition: Metastatic Breast Cancer
Interventions: Drug: Eribulin mesylate;   Other: Biologic: PEGylated recombinant human hyaluronidase (PEGPH20);   Other: Biologic: PEGylated recombinant human hyaluronidase
4 Recruiting Two Stage Study Of Single Dose PEGPH20 And Cetuximab In Patients With Pancreatic Adenocarcinoma Prior To Surgical Resection
Condition: Pancreatic Cancer
Interventions: Drug: PEGPH20;   Drug: Cetuximab;   Device: DW & DCE-MRI;   Other: blood draws
5 Completed Study of Gemcitabine + PEGPH20 vs Gemcitabine Alone in Stage IV Previously Untreated Pancreatic Cancer
Condition: Stage IV Pancreatic Cancer
Interventions: Drug: Gemcitabine;   Drug: PEGPH20+ gemcitabine
6 Completed Safety Study of PEGPH20 Given to Patients With Advanced Solid Tumors
Condition: Solid Tumor
Intervention: Drug: PEGPH20
7 Recruiting S1313, Combination Chemotherapy With or Without PEGPH20 in Treating Patients With Newly Diagnosed Metastatic Pancreatic Cancer
Condition: Metastatic Pancreatic Adenocarcinoma
Interventions: Drug: PEGPH20;   Drug: Oxaliplatin;   Drug: Leucovorin;   Drug: Irinotecan;   Drug: 5-fluorouracil
8 Completed Study of PEGPH20 With Initial Dexamethasone Premedication Given Intravenously to Patients With Advanced Solid Tumors
Condition: Solid Tumor
Intervention: Drug: PEGPH20
9 Recruiting A Phase 1b/2, Study of Pegylated Recombinant Human Hyaluronidase Combined With Docetaxel Versus Docetaxel Alone in Subjects With Recurrent Previously Treated Locally Advanced or Metastatic NSCLC.
Condition: Non Small Cell Lung Cancer
Interventions: Drug: PEGPH20;   Drug: Docetaxel
10 Recruiting Phase 1b Open-Label Study of PEGPH20 With Pembrolizumab
Conditions: NSCLC;   Gastric Cancer
Intervention: Drug: PEGPEM
11 Recruiting A Study of PEGylated Recombinant Human Hyaluronidase in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Participants With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma
Condition: Pancreatic Ductal Adenocarcinoma
Interventions: Other: Biological: PEGylated Recombinant Human Hyaluronidase (PEGPH20);   Drug: Placebo;   Drug: Nab-paclitaxel;   Drug: Gemcitabine
12 Recruiting PEGPH20, Gemicitabine and Nab-Paclitaxel for Pancreatic Ductal Adenocarcinoma
Condition: Adenocarcinoma
Interventions: Drug: PEGPH20;   Drug: Gemcitabine;   Drug: Nab-paclitaxel

Indicates status has not been verified in more than two years